Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
CA Urges Insurers to Make Things Easier for LA Wildfire Victims California Insurance Commissioner Ricardo Lara (D) issued a notice to residential property insurance companies in the state urging them...
Legislative Backlash Against AI Regulation A bill introduced in Montana ( SB 212 ) and a proposed constitutional amendment in New Hampshire ( CACR 6 ) would establish a right to compute, guaranteeing...
More PBM Regulation Under Consideration in IA After passing pharmacy benefit manager regulations last year, Iowa lawmakers are considering a pair of bills ( HSB 99 and SSB 1074 ) that would require all...
In late September, California became one of the first states to establish some ground rules for the use of artificial intelligence in healthcare when Gov. Gavin Newsom (D) signed into law AB 3030 and SB...
Bipartisan Bill to Ban Noncompete Clauses Introduced in OH Ohio Sens. Bill Blessing (R) and Bill DeMora (D) have introduced legislation ( SB 11 ) that would ban employers from enforcing noncompete clauses...
California joined a nationwide movement to tighten restrictions on pharmacy benefit managers with the approval of SB 966 days before adjourning its legislative session on Aug. 31. If signed by Gov. Gavin Newsom (D) the measure will establish licensing requirements for PBMs and require them to report to the state’s Department of Insurance the fees they charge pharmacies and the rebates they receive from drug manufacturers. The bill would also require PBMs to pass along 100% of those rebates to health plans or insurers. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
In 2021, Arkansas became the first state to pass a law requiring pharmaceutical manufacturers that participate in Medicaid to sell drugs to contract pharmacies at a discount under the federal 340B program. Louisiana followed suit in 2023. This year, Kansas (SB 28), Maryland (HB 1056), Mississippi (HB 728), Missouri (SB 751) and West Virginia (SB 325) enacted similar legislation. And other states, including New York (AB 7789), considered similar measures.
The recent legislative actions are pushback against the restriction of 340B drug sales by pharmaceutical companies, which contend the 340B program has expanded beyond its original intent. As of September 2023, 25 drugmakers had done so. (STATELINE)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.